ENTEROMEDICS INC. (NASDAQ:ETRM) Files An 8-K Results of Operations and Financial Condition

Item 2.02Results of Operations and Financial Condition.

On May16, 2017, EnteroMedics Inc. (the Company) issued a press
release announcing its financial results for the three months
ended March31, 2017. The Company also announced that it will be
hosting a conference call at 8:30 a.m.Eastern Time on May16, 2017
to discuss its financial results for the three months ended
March31, 2017 and to provide a business update.A copy of the
press release is furnished as Exhibit99.1 to this Current Report
on Form8-K and is incorporated herein by reference.

The information furnished herewith to Item 2.02 of this Current
Report and in Exhibit99.1 hereto is being furnished in accordance
with General Instruction B.2 of Form8-K and shall not be deemed
filed for purposes of Section18 of the Securities Exchange Act of
1934, as amended (the Exchange Act), or otherwise subject to the
liabilities of that section, nor shall it be deemed to be
incorporated by reference in any filing under the Securities Act
of 1933, as amended, or the Exchange Act, whether made before or
after the date hereof, regardless of any general incorporation
language in such filing.

Item 9.01 Financial Statements and
Exhibits.

(d) Exhibits.

About ENTEROMEDICS INC. (NASDAQ:ETRM)

EnteroMedics Inc. (EnteroMedics) is a medical device company. The Company is focused on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders. The Company’s neuroblocking technology, which is referred to as VBLOC therapy, is designed to intermittently block the vagus nerve. The Company’s initial product is the Maestro Rechargeable System, which uses VBLOC therapy to limit the expansion of the stomach, help control hunger sensations between meals, reduce the frequency and intensity of stomach contractions and produce a feeling of early and prolonged fullness. The Company’s VBLOC therapy is designed to block the gastrointestinal effects of the vagus nerve by replicating a vagotomy using high-frequency, low-energy electrical impulses to intermittently interrupt naturally occurring neural impulses on the vagus nerve between the brain and the digestive system.

ENTEROMEDICS INC. (NASDAQ:ETRM) Recent Trading Information

ENTEROMEDICS INC. (NASDAQ:ETRM) closed its last trading session up +1.45 at 6.10 with 2,316,039 shares trading hands.